Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
2.
Neuromuscul Disord ; 13(1): 42-8, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12467731

ABSTRACT

We have recently shown that syncoilin interacts with desmin in skeletal muscle and has a role in attaching and organising desmin filaments to the Z-lines. We have analysed patients with desmin accumulation and have found that syncoilin is both upregulated at the sarcolemma and aggregates with desmin indicating the presence of two distinct protein populations. Additional dystrophin-associated protein complex components also accumulate. The striking finding was that alpha-dystrobrevin-1 and neuronal nitric oxide synthase (nNOS) are almost completely lost from the membrane of these patients indicating that the myopathy may result from both the abnormal accumulation of proteins and an increase in ischaemic injury due to the loss of nNOS. We speculate that the loss of alpha-dystrobrevin from the membrane, and subsequent loss of nNOS, is due to the alpha-dystrobrevin-syncoilin-desmin interaction.


Subject(s)
Desmin/metabolism , Dystrophin-Associated Proteins , Intermediate Filament Proteins/metabolism , Muscle Proteins/metabolism , Muscular Diseases/metabolism , Adult , Biopsy , Cytoskeletal Proteins/metabolism , Dystrophin/metabolism , Female , Humans , Immunohistochemistry/methods , Male , Membrane Proteins/metabolism , Middle Aged , Muscular Diseases/pathology , Nitric Oxide Synthase/metabolism , Protein Isoforms , Sarcolemma/metabolism , Sarcolemma/pathology
3.
Endocr Relat Cancer ; 16(4): 1313-27, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19620250

ABSTRACT

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterized in man by parathyroid, pancreatic, pituitary and adrenal tumours. The MEN1 gene encodes a 610-amino acid protein (menin) which is a tumour suppressor. To investigate the in vivo role of menin, we developed a mouse model, by deleting Men1 exons 1 and 2 and investigated this for MEN1-associated tumours and serum abnormalities. Men1(+/-) mice were viable and fertile, and 220 Men1(+/-) and 94 Men1(+/+) mice were studied between the ages of 3 and 21 months. Survival in Men1(+/-) mice was significantly lower than in Men1(+/+) mice (<68% vs >85%, P<0.01). Men1(+/-) mice developed, by 9 months of age, parathyroid hyperplasia, pancreatic tumours which were mostly insulinomas, by 12 months of age, pituitary tumours which were mostly prolactinomas, and by 15 months parathyroid adenomas and adrenal cortical tumours. Loss of heterozygosity and menin expression was demonstrated in the tumours, consistent with a tumour suppressor role for the Men1 gene. Men1(+/-) mice with parathyroid neoplasms were hypercalcaemic and hypophosphataemic, with inappropriately normal serum parathyroid hormone concentrations. Pancreatic and pituitary tumours expressed chromogranin A (CgA), somatostatin receptor type 2 and vascular endothelial growth factor-A. Serum CgA concentrations in Men1(+/-) mice were not elevated. Adrenocortical tumours, which immunostained for 3-beta-hydroxysteroid dehydrogenase, developed in seven Men1(+/-) mice, but resulted in hypercorticosteronaemia in one out of the four mice that were investigated. Thus, these Men1(+/-) mice are representative of MEN1 in man, and will help in investigating molecular mechanisms and treatments for endocrine tumours.


Subject(s)
Adrenal Gland Neoplasms/etiology , Corticosterone/blood , Hypercalcemia/etiology , Hypophosphatemia/etiology , Pancreatic Neoplasms/etiology , Parathyroid Neoplasms/etiology , Pituitary Neoplasms/etiology , Proto-Oncogene Proteins/physiology , Adrenal Gland Neoplasms/pathology , Animals , Blotting, Western , Female , Hypercalcemia/pathology , Hypophosphatemia/pathology , Immunoenzyme Techniques , Loss of Heterozygosity , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Multiple Endocrine Neoplasia Type 1/genetics , Multiple Endocrine Neoplasia Type 1/pathology , Pancreatic Neoplasms/pathology , Parathyroid Neoplasms/pathology , Pituitary Neoplasms/pathology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL